Inhibikase Therapeutics (NYSE:IKT – Free Report) had its price target trimmed by HC Wainwright from $27.00 to $23.00 in a research note issued to investors on Tuesday, Benzinga reports. The firm currently has a buy rating on the stock. HC Wainwright also issued estimates for Inhibikase Therapeutics’ Q2 2024 earnings at ($0.58) EPS, Q4 2024 […]
Inhibikase Therapeutics (NYSE:IKT – Free Report) had its target price cut by HC Wainwright from $27.00 to $23.00 in a report issued on Tuesday morning, Benzinga reports. They currently have a buy rating on the stock. HC Wainwright also issued estimates for Inhibikase Therapeutics’ Q2 2024 earnings at ($0.58) EPS, Q4 2024 earnings at ($0.37) […]
Inhibikase Therapeutics (NYSE:IKT – Free Report) had its price target trimmed by HC Wainwright from $27.00 to $23.00 in a research note issued to investors on Tuesday, Benzinga reports. They currently have a buy rating on the stock. HC Wainwright also issued estimates for Inhibikase Therapeutics’ Q2 2024 earnings at ($0.58) EPS, Q4 2024 earnings […]
Inhibikase Therapeutics (NYSE:IKT – Get Free Report) had its target price cut by HC Wainwright from $27.00 to $23.00 in a report released on Tuesday, Benzinga reports. The firm currently has a “buy” rating on the stock. Inhibikase Therapeutics Trading Up 7.5 % Shares of Inhibikase Therapeutics stock opened at $1.86 on Tuesday. The firm’s […]
Head to Head Comparison: Kymera Therapeutics (NASDAQ:KYMR) vs. Inhibikase Therapeutics (NYSE:IKT) themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.